NO333544B1 - Farmasoytisk vaginalsammensetning til reduksjon eller lindring av uterin dysrytmi samt anvendelse derav - Google Patents
Farmasoytisk vaginalsammensetning til reduksjon eller lindring av uterin dysrytmi samt anvendelse derav Download PDFInfo
- Publication number
- NO333544B1 NO333544B1 NO20042208A NO20042208A NO333544B1 NO 333544 B1 NO333544 B1 NO 333544B1 NO 20042208 A NO20042208 A NO 20042208A NO 20042208 A NO20042208 A NO 20042208A NO 333544 B1 NO333544 B1 NO 333544B1
- Authority
- NO
- Norway
- Prior art keywords
- composition
- agent
- lidocaine
- treating agent
- concentration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 206010003119 arrhythmia Diseases 0.000 title claims abstract description 13
- 230000009467 reduction Effects 0.000 title claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 40
- 229920000642 polymer Polymers 0.000 claims abstract description 20
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960004194 lidocaine Drugs 0.000 claims abstract description 16
- 230000003531 anti-dysrhythmic effect Effects 0.000 claims abstract description 15
- 239000000227 bioadhesive Substances 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 229920000148 Polycarbophil calcium Polymers 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract description 6
- 229950005134 polycarbophil Drugs 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 21
- 229940124597 therapeutic agent Drugs 0.000 claims description 16
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 claims description 4
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims description 4
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 claims description 4
- 229960000449 flecainide Drugs 0.000 claims description 4
- 229960002409 mepivacaine Drugs 0.000 claims description 4
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 4
- 229960003404 mexiletine Drugs 0.000 claims description 4
- 229960001807 prilocaine Drugs 0.000 claims description 4
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 4
- 229960001549 ropivacaine Drugs 0.000 claims description 4
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 3
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims description 3
- 229960003150 bupivacaine Drugs 0.000 claims description 3
- 229960003976 etidocaine Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 29
- 208000000450 Pelvic Pain Diseases 0.000 abstract description 20
- 239000003589 local anesthetic agent Substances 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 7
- 210000001215 vagina Anatomy 0.000 abstract description 6
- 208000000509 infertility Diseases 0.000 abstract description 5
- 230000036512 infertility Effects 0.000 abstract description 5
- 231100000535 infertility Toxicity 0.000 abstract description 4
- 238000013268 sustained release Methods 0.000 abstract description 4
- 239000012730 sustained-release form Substances 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 16
- 230000036407 pain Effects 0.000 description 16
- 230000001684 chronic effect Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 230000003444 anaesthetic effect Effects 0.000 description 8
- 229960005015 local anesthetics Drugs 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 206010013935 Dysmenorrhoea Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 230000035587 bioadhesion Effects 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 239000003193 general anesthetic agent Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 201000009273 Endometriosis Diseases 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- -1 buipivacaine Chemical compound 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 150000003839 salts Chemical group 0.000 description 4
- 230000002620 ureteric effect Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229940035674 anesthetics Drugs 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 230000001839 systemic circulation Effects 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 208000034423 Delivery Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 208000022371 chronic pain syndrome Diseases 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002357 laparoscopic surgery Methods 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000018405 transmission of nerve impulse Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000009677 vaginal delivery Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DSAYAFZWRDYBQY-UHFFFAOYSA-N 2,5-dimethylhexa-1,5-diene Chemical compound CC(=C)CCC(C)=C DSAYAFZWRDYBQY-UHFFFAOYSA-N 0.000 description 1
- 208000005641 Adenomyosis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010058674 Pelvic Infection Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010046823 Uterine spasm Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940059082 douche Drugs 0.000 description 1
- 230000000142 dyskinetic effect Effects 0.000 description 1
- 208000016018 endometrial polyp Diseases 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- BLYOHBPLFYXHQA-UHFFFAOYSA-N n,n-bis(prop-2-enyl)prop-2-enamide Chemical compound C=CCN(CC=C)C(=O)C=C BLYOHBPLFYXHQA-UHFFFAOYSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 206010046811 uterine polyp Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33068401P | 2001-10-29 | 2001-10-29 | |
US10/278,912 US20030114394A1 (en) | 2001-10-29 | 2002-10-24 | Vaginally administered anti-dysrhythmic agents for treating pelvic pain |
PCT/EP2002/012042 WO2003037381A1 (fr) | 2001-10-29 | 2002-10-28 | Agents antidysrythmiques administres par voie vaginale utilises pour traiter les douleurs pelviennes et la sterilite |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20042208L NO20042208L (no) | 2004-07-29 |
NO333544B1 true NO333544B1 (no) | 2013-07-08 |
Family
ID=26959337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20042208A NO333544B1 (no) | 2001-10-29 | 2004-05-28 | Farmasoytisk vaginalsammensetning til reduksjon eller lindring av uterin dysrytmi samt anvendelse derav |
Country Status (34)
Country | Link |
---|---|
US (1) | US20030114394A1 (fr) |
EP (2) | EP1441770B1 (fr) |
JP (2) | JP2005511564A (fr) |
KR (2) | KR20100088718A (fr) |
CN (1) | CN100404072C (fr) |
AR (1) | AR037048A1 (fr) |
AT (2) | ATE451123T1 (fr) |
AU (1) | AU2002350644B2 (fr) |
BR (1) | BR0213585A (fr) |
CA (1) | CA2465132C (fr) |
CY (2) | CY1106000T1 (fr) |
DE (2) | DE60216495T2 (fr) |
DK (2) | DK1441770T3 (fr) |
ES (2) | ES2275928T3 (fr) |
GE (1) | GEP20094614B (fr) |
HK (2) | HK1063293A1 (fr) |
HR (1) | HRP20040479B1 (fr) |
HU (1) | HUP0402389A3 (fr) |
IL (3) | IL161513A0 (fr) |
MA (1) | MA26230A1 (fr) |
ME (1) | ME00255B (fr) |
MX (1) | MXPA04003976A (fr) |
MY (2) | MY149482A (fr) |
NO (1) | NO333544B1 (fr) |
NZ (1) | NZ532295A (fr) |
PE (1) | PE20030692A1 (fr) |
PL (2) | PL402549A1 (fr) |
PT (2) | PT1764111E (fr) |
RS (1) | RS51414B (fr) |
RU (2) | RU2476212C2 (fr) |
SI (2) | SI1441770T1 (fr) |
UA (1) | UA90077C2 (fr) |
WO (1) | WO2003037381A1 (fr) |
ZA (1) | ZA200402944B (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7341737B2 (en) * | 1997-06-11 | 2008-03-11 | Kimberly-Clark Worldwide, Inc. | Medicated tampon |
US7344732B2 (en) * | 2002-01-10 | 2008-03-18 | Kimberly-Clark Worldwide, Inc. | Medicated tampon |
CH697081A5 (de) * | 2002-01-22 | 2008-04-30 | Andreas F Dr Schaub | Zusammensetzung für die Unterstützung der Geburt eines menschlichen Föten. |
US20050244402A1 (en) * | 2004-04-30 | 2005-11-03 | Villanueva Julie M | Absorption of pain-causing agents |
DE102004054552A1 (de) * | 2004-11-11 | 2006-05-18 | Hcb Happy Child Birth Holding Ag | Neue Zusammensetzung zur Erleichterung der Humangeburt |
US7993667B2 (en) | 2005-03-25 | 2011-08-09 | Kimberly-Clark Worldwide, Inc. | Methods of manufacturing a medicated tampon assembly |
US7744556B2 (en) | 2005-03-25 | 2010-06-29 | Kimberly-Clark Worldwide, Inc. | Delivery tube assembly for an applicator |
US7919453B2 (en) | 2005-03-25 | 2011-04-05 | Kimberly-Clark Worldwide, Inc. | Dosage cap assembly for an applicator |
US7708726B2 (en) | 2005-04-28 | 2010-05-04 | Kimberly-Clark Worldwide, Inc. | Dosage form cap for an applicator |
US20070253994A1 (en) * | 2006-04-28 | 2007-11-01 | Medtronic, Inc. | Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain |
EP2068958B1 (fr) * | 2006-09-28 | 2016-10-19 | Cook Medical Technologies LLC | Dispositif médical comprenant un anesthésique et son procédé de fabrication |
US20080108824A1 (en) * | 2006-09-28 | 2008-05-08 | Med Institute, Inc | Medical Devices Incorporating a Bioactive and Methods of Preparing Such Devices |
US20080082038A1 (en) * | 2006-09-28 | 2008-04-03 | Vance Products Incorporated, D/B/A/ Cook Urological Incorporated | Medical Device including a Bioactive in a Non-ionic and an Ionic Form and Methods of Preparation Thereof |
CA2698143C (fr) * | 2007-06-26 | 2016-01-19 | Warner Chilcott Company, Llc | Dispositifs d'administration intravaginale de medicament permettant la liberation de macromolecules et de medicaments hydrosolubles |
US8956642B2 (en) * | 2008-04-18 | 2015-02-17 | Medtronic, Inc. | Bupivacaine formulation in a polyorthoester carrier |
US8940315B2 (en) * | 2008-04-18 | 2015-01-27 | Medtronic, Inc. | Benzodiazepine formulation in a polyorthoester carrier |
MX2010011880A (es) * | 2008-04-29 | 2011-05-25 | Pharnext | Nuevos enfoques terapeuticos para tratar la enfermedad del alzheimer y trastornos relacionados mediante una modulacion de la respuesta de estres celular. |
BRPI0803568B8 (pt) * | 2008-08-14 | 2021-05-25 | Biolab San Us Farm Ltda | composição mucoaderente |
RU2538674C2 (ru) * | 2012-09-10 | 2015-01-10 | Открытое акционерное общество "Всероссийский научный центр по безопасности биологически активных веществ" (ОАО "ВНЦ БАВ") | Фармацевтическая композиция, обладающая пролонгированной противоаритмической активностью |
US9700549B2 (en) | 2013-10-03 | 2017-07-11 | David Wise | Compositions and methods for treating pelvic pain and other conditions |
JP6654057B2 (ja) * | 2016-02-10 | 2020-02-26 | 国立大学法人 筑波大学 | 局所麻酔薬を含有するポリイオンコンプレックスを有効成分とする局所疼痛制御用組成物 |
WO2017165707A1 (fr) * | 2016-03-24 | 2017-09-28 | Juniper Pharmaceuticals, Inc. | Administration vaginale d'agents pour le traitement et la prévention de la douleur associée à des procédures médicales gynécologiques |
BR102018008324A2 (pt) * | 2018-04-25 | 2019-11-05 | Laboratorios Ferring Ltda | composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3387419A (en) * | 1965-10-22 | 1968-06-11 | Kamberg Henry | Decking with trim strip |
WO1985002092A1 (fr) * | 1983-11-14 | 1985-05-23 | Bio-Mimetics Inc. | Compositions bio-adhesives et procedes de traitement a l'aide de celles-ci |
US5446070A (en) * | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5234957A (en) * | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5387419A (en) * | 1988-03-31 | 1995-02-07 | The University Of Michigan | System for controlled release of antiarrhythmic agents |
ATE135905T1 (de) * | 1989-11-03 | 1996-04-15 | Riker Laboratories Inc | Bioadhäsive zusammensetzung und pflaster |
US5332576A (en) * | 1991-02-27 | 1994-07-26 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
IT1250421B (it) * | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive. |
US5700485A (en) * | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
US5508045A (en) * | 1992-10-09 | 1996-04-16 | The Regents Of The University Of California | Method and agents for control and management of labor during pregnancy |
US5543150A (en) * | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
US5667492A (en) * | 1994-10-07 | 1997-09-16 | Columbia Laboratories, Inc. | Use and composition of an anti-sexually transmitted diseases formulation |
GB9610359D0 (en) * | 1996-05-17 | 1996-07-24 | Edko Trading Representation | Pharmaceutical compositions |
US5663492A (en) * | 1996-06-05 | 1997-09-02 | Alapati; Rama Rao | System for continuous analysis and modification of characteristics of a liquid hydrocarbon stream |
US5985861A (en) * | 1996-11-04 | 1999-11-16 | Columbia Laboratories, Inc. | Progesterone for treating or reducing ischemia |
US5993856A (en) * | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
US5977143A (en) * | 1997-02-15 | 1999-11-02 | Edelstam; Greta | Medicament against infertility which reduces phagocytosis of spermatozoa in women |
US6210710B1 (en) * | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
CA2207227A1 (fr) * | 1997-06-09 | 1998-12-09 | Johnson & Johnson Inc. | Tapis de germination de semences |
US6197327B1 (en) * | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
US5989535A (en) * | 1997-08-15 | 1999-11-23 | Soma Technologies | Polymeric bioadhesive emulsions and suspensions and methods of treatment |
DE69819748T2 (de) * | 1997-09-12 | 2004-09-30 | Columbia Laboratories (Bermuda) Ltd. | Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen |
US6248358B1 (en) * | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
EP1021204B1 (fr) * | 1997-09-26 | 2005-12-28 | Noven Pharmaceuticals, Inc. | Compositions bioadhesives et methodes d'administration locale d'agents actifs |
US6135153A (en) * | 1998-01-02 | 2000-10-24 | Cleland, Sr. John | Anesthesia delivery systems and methods |
EP1075535A4 (fr) * | 1998-05-07 | 2006-01-18 | Univ Maryland | Methode de diagnostic et de traitement du syndrome de douleur pelvienne chronique |
US6207696B1 (en) * | 1998-09-15 | 2001-03-27 | Cytos Pharamaceuticals, Llc | Compositions and methods for the prophylaxis and treatment of dysmenorrhea, endometriosis, and pre-term labor, using histidine |
US6486207B2 (en) * | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6264973B1 (en) * | 1999-08-26 | 2001-07-24 | Fei Enterprises, Ltd. | Apparatus and method for anesthetizing the cervical region of a female |
AU7331300A (en) * | 1999-08-27 | 2001-03-26 | Merck & Co., Inc. | Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome |
US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
-
2002
- 2002-10-24 US US10/278,912 patent/US20030114394A1/en not_active Abandoned
- 2002-10-28 PL PL402549A patent/PL402549A1/pl not_active Application Discontinuation
- 2002-10-28 NZ NZ532295A patent/NZ532295A/en not_active IP Right Cessation
- 2002-10-28 PT PT06024500T patent/PT1764111E/pt unknown
- 2002-10-28 AT AT06024500T patent/ATE451123T1/de active
- 2002-10-28 DE DE60216495T patent/DE60216495T2/de not_active Expired - Lifetime
- 2002-10-28 PL PL02369790A patent/PL369790A1/xx not_active IP Right Cessation
- 2002-10-28 SI SI200230452T patent/SI1441770T1/sl unknown
- 2002-10-28 MX MXPA04003976A patent/MXPA04003976A/es active IP Right Grant
- 2002-10-28 RU RU2008133235/15A patent/RU2476212C2/ru not_active IP Right Cessation
- 2002-10-28 EP EP02785326A patent/EP1441770B1/fr not_active Expired - Lifetime
- 2002-10-28 IL IL16151302A patent/IL161513A0/xx unknown
- 2002-10-28 GE GEAP20028235A patent/GEP20094614B/en unknown
- 2002-10-28 KR KR1020107016839A patent/KR20100088718A/ko not_active Application Discontinuation
- 2002-10-28 KR KR1020047006271A patent/KR20050040820A/ko not_active Application Discontinuation
- 2002-10-28 CN CNB028215656A patent/CN100404072C/zh not_active Expired - Fee Related
- 2002-10-28 PT PT02785326T patent/PT1441770E/pt unknown
- 2002-10-28 WO PCT/EP2002/012042 patent/WO2003037381A1/fr active Application Filing
- 2002-10-28 ES ES02785326T patent/ES2275928T3/es not_active Expired - Lifetime
- 2002-10-28 UA UA20040403211A patent/UA90077C2/uk unknown
- 2002-10-28 ME MEP-2008-349A patent/ME00255B/fr unknown
- 2002-10-28 RU RU2004116346/15A patent/RU2345758C2/ru not_active IP Right Cessation
- 2002-10-28 AT AT02785326T patent/ATE346614T1/de active
- 2002-10-28 BR BR0213585-0A patent/BR0213585A/pt active Search and Examination
- 2002-10-28 HU HU0402389A patent/HUP0402389A3/hu unknown
- 2002-10-28 AU AU2002350644A patent/AU2002350644B2/en not_active Ceased
- 2002-10-28 EP EP06024500A patent/EP1764111B1/fr not_active Expired - Lifetime
- 2002-10-28 SI SI200230886T patent/SI1764111T1/sl unknown
- 2002-10-28 AR ARP020104079A patent/AR037048A1/es unknown
- 2002-10-28 CA CA2465132A patent/CA2465132C/fr not_active Expired - Fee Related
- 2002-10-28 RS YUP-367/04A patent/RS51414B/en unknown
- 2002-10-28 MY MYPI20024018A patent/MY149482A/en unknown
- 2002-10-28 MY MYPI2010004778A patent/MY145215A/en unknown
- 2002-10-28 PE PE2002001058A patent/PE20030692A1/es not_active Application Discontinuation
- 2002-10-28 DK DK02785326T patent/DK1441770T3/da active
- 2002-10-28 ES ES06024500T patent/ES2336238T3/es not_active Expired - Lifetime
- 2002-10-28 DE DE60234725T patent/DE60234725D1/de not_active Expired - Lifetime
- 2002-10-28 DK DK06024500.8T patent/DK1764111T3/da active
- 2002-10-28 JP JP2003539721A patent/JP2005511564A/ja active Pending
-
2004
- 2004-04-19 IL IL161513A patent/IL161513A/en not_active IP Right Cessation
- 2004-04-19 ZA ZA2004/02944A patent/ZA200402944B/en unknown
- 2004-04-29 MA MA27663A patent/MA26230A1/fr unknown
- 2004-05-27 HR HR20040479A patent/HRP20040479B1/xx not_active IP Right Cessation
- 2004-05-28 NO NO20042208A patent/NO333544B1/no not_active IP Right Cessation
- 2004-08-13 HK HK04106073A patent/HK1063293A1/xx not_active IP Right Cessation
-
2007
- 2007-02-09 CY CY20071100173T patent/CY1106000T1/el unknown
- 2007-09-20 HK HK07110257.0A patent/HK1102221A1/xx not_active IP Right Cessation
-
2010
- 2010-02-25 CY CY20101100180T patent/CY1110288T1/el unknown
-
2011
- 2011-02-17 IL IL211288A patent/IL211288A/en not_active IP Right Cessation
- 2011-05-31 JP JP2011121273A patent/JP2011201909A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO333544B1 (no) | Farmasoytisk vaginalsammensetning til reduksjon eller lindring av uterin dysrytmi samt anvendelse derav | |
AU2002350644A1 (en) | Vaginally administerd anti-dysrhythmic agents for treating pelvic pain and infertility | |
JP2010248232A (ja) | 膣感染を処置又は予防するための低濃度のペルオキサイド | |
US8425892B2 (en) | Extended, controlled-release pharmaceutical compositions using charged polymers | |
US20080182841A1 (en) | Vaginally administered anti-dysrhythmic agents for treating pelvic pain | |
US20030091642A1 (en) | Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof | |
EP1556015B1 (fr) | Compositions pharmaceutiques a liberation maitrisee et prolongee renfermant des polymeres charges | |
WO2017165707A1 (fr) | Administration vaginale d'agents pour le traitement et la prévention de la douleur associée à des procédures médicales gynécologiques | |
AU2014252196B2 (en) | Progesteron receptor modulators for use in the therapy of uterine fibroids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |